Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
NEW YORK--(BUSINESS WIRE)--Mar 25, 2025--
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France.
Mini Oral Presentation Overview:
Title: Taletrectinib vs crizotinib in ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison
Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI School of Medicine
Date: Thursday, March 27, 2025
Session Time: 4:00 p.m. – 5:05 p.m. CET / 11:00 a.m. – 12:05 p.m. ET
Session: Mini Oral Session 1
Presentation Number: LBA2
The materials will be made available in the Publications section of Nuvation Bio's website after the presentation.
About Taletrectinib
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study.
Based on pooled results of the TRUST-I and TRUST-II clinical studies, the U.S. FDA has accepted and granted Priority Review to Nuvation Bio's NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025. The U.S. FDA previously granted taletrectinib Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs, and Orphan Drug Designation for the treatment of patients with ROS1+ NSCLC and other NSCLC indications. In January 2025, China's NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC.
About Nuvation Bio
Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio's programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com or follow the Company on LinkedIn and X (@nuvationbioinc).
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL ONCOLOGY
SOURCE: Nuvation Bio Inc.
Copyright Business Wire 2025.
PUB: 03/25/2025 08:00 AM/DISC: 03/25/2025 08:00 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential
Brookfield Infrastructure has increased its high-yielding payout every year since its formation. PepsiCo is an elite dividend stock. Prologis is growing its dividend much faster than the average dividend stock. 10 stocks we like better than PepsiCo › Dividend-paying stocks can be great investments. They can enable you to generate some passive income, providing a real return. In addition, dividend stocks have historically produced strong total returns as they've grown their earnings and shareholder payouts, driving stock price appreciation. Brookfield Infrastructure (NYSE: BIPC)(NYSE: BIP), PepsiCo (NASDAQ: PEP), and Prologis (NYSE: PLD) currently stand out among dividend stocks. The trio has excellent records of paying growing dividends. On top of that, they currently offer attractive yields of more than 3%, partly due to drops in their stock prices this year. Because of that, they offer compelling blends of dividend income and upside potential. Shares of Brookfield Infrastructure have declined by nearly 10% from their 52-week high. That slump has pushed the global infrastructure company's dividend yield up to 4.2%. The company's stock price has also slumped, even though it's having another good year, and its funds from operations (FFO) rose 5% in the first quarter, powered by inflation-driven rate increases, recently completed expansion projects, and acquisitions closed in the past year. Brookfield Infrastructure has a terrific record of paying dividends. It has increased its payment in all 16 years since its formation, growing it at a 9% compound annual rate. The company expects to continue increasing its payout in the future, targeting 5% to 9% annual growth. It sees a trio of organic growth drivers (inflation-driven rate increases, volume growth as the global economy expands, and expansion projects), increasing its FFO per share by 6% to 9% per year. On top of that, the company has an excellent record of making accretive acquisitions funded by recycling capital. It recently agreed to invest $500 million in the acquisition of Colonial Enterprises, which owns a leading U.S. refined products pipeline system. It also partnered with GATX Corporation to buy Wells Fargo's rail operating lease portfolio (consisting of 105,000 railcars) for $4.4 billion. It's also acquiring Wells Fargo's rail finance lease portfolio (23,000 railcars and 440 locomotives) in a separate deal. Brookfield estimates that acquisitions like these will help push its FFO growth rate above 10% annually. PepsiCo stock has slumped more than 25% from its 52-week high. That plunge has propelled its dividend yield to 4.4%. That's a tasty level for a company with a long history of satisfying investors' cravings for more dividend income. The food and beverage giant recently increased its dividend payment by another 5%. That extended its growth streak to 53 straight years, enough to qualify PepsiCo as an elite Dividend King. PepsiCo's stock is down due to concerns that tariffs, a slowing economy, and changing consumer tastes will impact the company's growth. On the one hand, the company is seeing some impact from those headwinds this year. It now expects its earnings per share to be at the same level as last year's, compared to the mid-single-digit growth rate it initially expected. However, the company has a resilient business and expects its growth to reaccelerate in the coming years. It has been investing heavily in the strategic transformation of its portfolio to healthier food and beverage options, including buying Poppi, Siete, and Sabra in recent quarters. These investments should pay dividends for the company in the coming years by reigniting its earnings growth engine, which should enable PepsiCo to continue increasing its dividend. Prologis stock has slumped more than 15% this year. That sell-off has helped nudge its dividend yield up to 3.7%. The leading industrial real estate investment trust (REIT) has been under some pressure due to slowing demand for warehouse space. However, the company is still performing well amid all the uncertainty. Its core FFO per share increased 11% in the first quarter as it continues to sign new leases at much higher rates compared to the price point of expiring contracts on the same space. Meanwhile, the long-term demand picture for warehouse space remains robust. "Over the long term, limited new supply and high construction costs support continued rent growth," commented CEO and co-founder Hamid Moghadam in the first-quarter earnings press release. That should enable the company to capture higher rental rates on its existing properties and continue developing new warehouses. In addition, Prologis is using some of its land to build data centers to capitalize on the growing demand for these properties to support increased digitalization and AI technology. Prologis' growth prospects should enable the REIT to continue increasing its dividend. It has grown its payout at a 13% compound annual rate over the past five years. That's faster than the S&P 500 (5%) and REIT sector average (6%). Brookfield Infrastructure, PepsiCo, and Prologis offer investors the best of both worlds. They pay dividends that yield more than double the S&P 500's average (less than 1.5%), and they have compelling upside potential from their earnings growth and an eventual recovery in their stock prices. Because of that, they could produce strong total returns from here, making them great dividend stocks to buy right now. Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Matt DiLallo has positions in Brookfield Infrastructure, Brookfield Infrastructure Partners, PepsiCo, and Prologis. The Motley Fool has positions in and recommends Prologis. The Motley Fool recommends Brookfield Infrastructure Partners and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy. 3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential was originally published by The Motley Fool
Associated Press
3 hours ago
- Associated Press
Lead Plaintiff Deadline is June 16, 2025 for Investors of Ibotta, Inc.
NEW YORK, NY - June 8, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ibotta, Inc. ('Ibotta' or the 'Company') (NYSE: IBTA) on behalf of Ibotta investors. CLICK HERE TO JOIN THE CASE If you are an investor in Ibotta and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than June 16, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to consumers through the Ibotta Performance Network. On April 18, 2024, Ibotta conducted its Initial Public Offering ('IPO'), offering 6,560,700 million shares of Class A common stock at a price of $88 per share. The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that; (i) Ibotta's data measurement system did not provide accurate, precise, and real time client campaign and consumer data measurement; (ii) the Company's business mix had shifted and was generating less revenue; and (iii) Ibotta had 'exhausted' its clients' budgets, negatively impacting fourth quarter 2024 revenue and expected first quarter 2025 revenue. According to the action, on February 26, 2025, after market hours, in connection with reporting fourth quarter 2024 and full year 2024 financial results, Ibotta's CEO Bryan W. Leach ('CEO Leach') explained just how deficient Ibotta's data measurement technology was by stating that 'it has become clear that we need to bring to market a more rigorous form of measurement that goes beyond the industry standard return on ad spend, or ROAS, framework.' Further CEO Leach allegedly announced that Ibotta would transform into a programmatic advertising company, which according to the complaint demonstrates that, at the time of the IPO, Ibotta's data measurement infrastructure was not suited for heavy reliance on third party platforms. On this news, the price of Ibotta's stock fell $29.08, or nearly 46%, to close at $34.09 on February 27, 2025, more than 60% lower than the IPO price of $88 per share. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. View the original release on
Yahoo
5 hours ago
- Yahoo
Tennis great Stan Smith on life lessons, Arthur Ashe's legacy and his namesake shoes
Fancy footwork won him Wimbledon. Simple footwear won him everything since. 'The shoe has had a life of its own,' said Stan Smith, 78, whose eponymous Adidas kicks, with their timeless lines and leather uppers, are the king of all tennis sneakers with more than 100 million sold. 'People from all walks of life have embraced them.' Advertisement Not surprisingly, Smith has a head for business to match his feet for tennis. With that in mind, he and longtime business partner Gary Niebur wrote the just-released 'Winning Trust: How to Create Moments that Matter,' aimed at helping businesses develop stronger relationships with their clients, with tips that readers can apply to their personal relationships and to sports. 'The book is about developing relationships that can elevate the element of trust, which is a depreciating asset in today's world,' Smith said this week in a call from the French Open. When it comes to building and maintaining high-stakes relationships, Smith and Niebur have distilled their process into five key elements they call SERVE, a recurring theme throughout the book. That's an acronym for Strategize, Engage, Recreate, Volley and Elevate. Advertisement For instance, recreate — as in recreation — means to build bonds through fun shared experiences, and volley means to trade ideas back and forth to find solutions. 'When people realize that you care more about the relationship than the transaction,' Niebur said, 'trust follows.' A onetime standout at Pasadena High and USC, Smith was a close friend of the late Arthur Ashe, the UCLA legend whose name graces the main stadium court at Flushing Meadows, N.Y., home of the U.S. Open. This year marks the 50th anniversary of Ashe's victory at Wimbledon, when he beat the heavily favored Jimmy Connors in the 1975 final. Ashe remains the only Black man to win the singles title at that storied tournament. Advertisement 'Arthur was a good friend,' Smith said. 'He made a huge impact, and much more of an impact in the last few years of his life when he was fighting AIDS and the heart fund, and obviously for equal rights.' Arthur Ashe celebrates after winning the Wimbledon men's singles title in 1975. (Associated Press) Ashe, who contracted HIV from a blood transfusion he received during heart-bypass surgery, died in 1993. Although he was four years older than Smith, the two developed a close friendship when they traveled the globe as Davis Cup teammates and rising professionals. Smith has vivid memories of traveling with him, Ashe in his 'Citizen of the World' T-shirt with his nose forever buried in a newspaper or magazine. Smith was ranked No. 1 in the U.S. at the time, two spots ahead of his pal, yet the wildly popular Ashe always got top billing. Advertisement 'When we went to Africa, I was the other guy who played against him in all these exhibitions,' Smith told The Times in 2018. 'They would introduce him as Arthur Ashe, No. 1 player in the U.S., No. 1 in the world, one of the greatest players to ever play the game … and Stan Smith, his opponent.' Smith laughs about that now, but it used to chafe him. Finally, he raised the issue with his buddy. Recalled Smith in that 2018 interview: 'Arthur came up to me and said, 'I'm sorry about that. If we do a tour of Alabama, I'll carry your rackets for you.' He was in tune with everything. 'Arthur was a quiet leader walking a tightrope between a traditionally white sport and the black community.' Advertisement Smith will be at Wimbledon next month, where his UCLA friend will be honored. As for his shoes, they're everywhere, and have been since the 1970s. Adidas originally developed the shoe for French player Robert Haillet in the mid-1960s, and the sneakers were known as the 'Haillet.' In 1972, the company switched to Smith, naming the shoes in his honor and printing a tiny picture of his mustachioed face on them. There were subtle changes to the Haillet, including a notch in the tongue for laces to pass through and a heel better shaped to protect the Achilles tendon. They sold like crazy. In 1988, Stan Smiths made the "Guinness Book of World Records" for the most pairs sold at 22 million. Yet that was only the beginning as sales surged with the release of the Stan Smith II and retro Stan Smith 80s. The most common ones were solid white with touch of green on the back. Advertisement 'Hugh Grant turned around last year in the [Wimbledon] royal box and said, `First girl I ever kissed, I was wearing your shoes,'' Smith told The Times in 2022. 'Another guy said he met this girl when he was wearing my shoes. It was so meaningful that they both wore the shoes for their wedding seven years later. 'It started off as a tennis shoe. Now it's a fashion shoe.' Tennis great Stan Smith with his namesake Adidas shoe. (Sam Farmer / Los Angeles Times) Smith's personal collection has climbed to more than 100 size 13s in all sorts of colors, including his favorite pair in cardinal and black, an homage to his USC roots. In 2022, to commemorate the 50th anniversary of Smith's Wimbledon singles title, Adidas gave all of its sponsored players a pair of shoes with SW19 on the tongue — Wimbledon's postcode — with the date of that match against Ilie Nastase inside the right shoe and the score of the match inside the left. Advertisement At Wimbledon this year, the spotlight swings to the other side of Los Angeles, to an unforgettable Bruin, a sports hero who impacted so many lives. For Smith, his friendship with Ashe was an early example in his career of a relationship forged with trust. The book, incidentally, is affixed with a unique and fitting page marker. A shoelace. Get the best, most interesting and strangest stories of the day from the L.A. sports scene and beyond from our newsletter The Sports Report. This story originally appeared in Los Angeles Times.
